269 related articles for article (PubMed ID: 26952006)
1. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Bitzer M; Horger M; Giannini EG; Ganten TM; Wörns MA; Siveke JT; Dollinger MM; Gerken G; Scheulen ME; Wege H; Zagonel V; Cillo U; Trevisani F; Santoro A; Montesarchio V; Malek NP; Holzapfel J; Herz T; Ammendola AS; Pegoraro S; Hauns B; Mais A; Lauer UM; Henning SW; Hentsch B
J Hepatol; 2016 Aug; 65(2):280-8. PubMed ID: 26952006
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.
Tak WY; Ryoo BY; Lim HY; Kim DY; Okusaka T; Ikeda M; Hidaka H; Yeon JE; Mizukoshi E; Morimoto M; Lee MA; Yasui K; Kawaguchi Y; Heo J; Morita S; Kim TY; Furuse J; Katayama K; Aramaki T; Hara R; Kimura T; Nakamura O; Kudo M
Invest New Drugs; 2018 Dec; 36(6):1072-1084. PubMed ID: 30198057
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.
Streubel G; Schrepfer S; Kallus H; Parnitzke U; Wulff T; Hermann F; Borgmann M; Hamm S
Sci Rep; 2021 May; 11(1):9587. PubMed ID: 33953226
[TBL] [Abstract][Full Text] [Related]
5. Activation of mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC inhibitor resminostat in hepatocellular carcinoma cells.
Fu M; Shi W; Li Z; Liu H
Biochem Biophys Res Commun; 2016 Sep; 477(4):527-533. PubMed ID: 27144317
[TBL] [Abstract][Full Text] [Related]
6. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
7. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
[TBL] [Abstract][Full Text] [Related]
8. Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis.
Soukupova J; Bertran E; Peñuelas-Haro I; Urdiroz-Urricelqui U; Borgman M; Kohlhof H; Fabregat I
Oncotarget; 2017 Dec; 8(66):110367-110379. PubMed ID: 29299154
[TBL] [Abstract][Full Text] [Related]
9. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
10. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
[TBL] [Abstract][Full Text] [Related]
12. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Ueno M; Morizane C; Furukawa M; Sakai D; Komatsu Y; Nakai Y; Tsuda M; Ozaka M; Mizuno N; Muto M; Fukutomi A; Ikeda M; Tsuji A; Katanuma A; Moriwaki T; Kajiwara T; Ishii H; Negoro Y; Shimizu S; Nemoto N; Kobayashi S; Makino K; Furuse J
Cancer Med; 2021 Mar; 10(6):2088-2099. PubMed ID: 33635605
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Gabrielson A; Tesfaye AA; Marshall JL; Pishvaian MJ; Smaglo B; Jha R; Dorsch-Vogel K; Wang H; He AR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1073-9. PubMed ID: 26449224
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
Cheng AL; Kang YK; He AR; Lim HY; Ryoo BY; Hung CH; Sheen IS; Izumi N; Austin T; Wang Q; Greenberg J; Shiratori S; Beckman RA; Kudo M;
J Hepatol; 2015 Oct; 63(4):896-904. PubMed ID: 26071796
[TBL] [Abstract][Full Text] [Related]
18. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
19. Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Patt Y; Rojas-Hernandez C; Fekrazad HM; Bansal P; Lee FC
Oncologist; 2017 Oct; 22(10):1158-e116. PubMed ID: 28687627
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T
BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
